- Free Global Shipping On Purchases Of 3 Months Or More
Long Awaited Results Are Here
Clinical Study of VigRX Plus® With Real Individuals is Now Complete
- 61% improvement in reported sexual drive and desire
- 71% rise in sexual satisfaction
- 58% enhancement of hardness
- 63% increase of staying power
- 22% rise in the number of orgasms achieved
*Individual results may vary
In the RCT, participants were selected at random to receive either a placebo or VigRX Plus®. Neither the participants nor the people administrating and evaluating treatment were aware of which pills were received by any given individual.
For the sake of convenience, you can skip the 56-page report and continue to read our summary of the most noteworthy findings below
The organization is committed to providing top quality verifiable data and was among the first to adopt Good Clinical Practices (GCP) – the highest standard of quality control used in the study of human systems.
Vedic Lifesciences Pvt. Ltd is currently one of the top companies for their compliance with the FTC and FDA standards.

Protocols of the RCT were officially approved by the Independent Institutional Ethics Committee (IEC) before testing commenced.
Findings were evaluated using the International Index of Erectile Function (IIEF), a system of assessment with international acclaim and a proven track record.
- Firmness and frequency of erections
- Frequency of partner penetration
- Ability to maintain an erection throughout intercourse, until completion
The participants were recruited from a number of volunteers, and selected for their high levels of health (to ensure a controlled assessment of potential side effects).
For this reason, none of the participants had a history of severe mental health issues, alcoholism, heart conditions, liver conditions, STDs, kidney conditions, spinal injuries, diabetes, or deformed reproductive organs.
None of the participants were using any form of medication known to result in sexual dysfunction at the time of the trial. It was also ensured that no participant had a pregnant sexual partner.
Now that we’ve covered the basics of the manner in which the tests were conducted, let’s take a more in-depth look at the proven results of the trial:
61% Improvement in Reported Sexual Drive and Desire


71 % Rise in sexual satisfaction

58% Enhancement of hardness
Due to the powerful effects of VigRX Plus®, female partners reported a 58.97% increase in the ability of the participant to penetrate them. VigRX Plus® increased the strength and fullness of the erect participants for fast, effective penetration.
This was accompanied by the testimonies of enhanced satisfaction and extra pleasurable overall experience. The data was collected by means of the EDITS questionnaire, which was specifically developed as a tool for the assessment of erectile dysfunction products.

63% Increase in Staying Power
After the full 84 days of supplementing with our star product, VigRX Plus®, participants experienced an increased ability to maintain a powerful erection throughout penetration.
The erection was notably firmer, thicker, and fuller for the duration of intercourse.

22% Rise in the number of orgasms achieved
Over the 84 days of clinical trial, participants taking the VigRX Plus® were noted to achieve a whopping 22.49% increase in the number of orgasms. This number speaks to the success of the product and certainly to the satisfaction of participants and their partners.
Who doesn’t want more orgasms? We thought as much.

VigRX Plus® Study References
-
National Institutes of Health Consensus Development Panel on impotence: JAMA 1993, 270(1):83–90
-
Aytac A, McKinlay JB, Krane RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. Br J Urol Int 1999, 84:450–456
-
Tamler R, Mechanick JI: Dietary supplements and nutraceuticals in the management of andrologic disorders. Endocrinol Metab Clin North Am 2007, 36(2):533–552.
-
Dietary Supplement Health and Education Act of 1994 (DSHEA).
-
Glisson JK, Walker LA: How physicians should evaluate dietary supplements. Am J Med 2010, 123(7):577–582
-
Smitasirib Y, D’Souzac P, Neal-Kababickd J, Schauss AG: An Initial Evaluation of the Safety, Efficacy and Purity of VigRX, a Herbal Combination Formula, for the Enhancement of Male Sexual Health. The Open Natural Products Journal 2010, 3:10–19.
-
Chitaley K, Webb RC, Mills TM: Rho-kinase as a potential target for the treatment of erectile dysfunction. Drug News Perspect 2001, 14(10):601–606
-
Barnes PM, Powell-Griner E, McFann K, Nahin RL: Complementary and alternative medicine use among adults: United States, 2002. Advance data from vital and health statistics; no 343. Hyattsville, Maryland: National Center for Health Statistics; 2004
-
Marwick C: Survey says patients expect little physician help on sex. JAMA 1999, 281(23):2173–2174.
-
de Andrade E, de Mesquita AA, Claro Jde A, de Andrade PM, Ortiz V, Paranhos M, Srougi M: Study of the efficacy of Korean Red Ginseng in the
-
Gauthaman K, Ganesan AP: The hormonal effects of Tribulus terrestris and its role in the management of male erectile dysfunction–an evaluation using primates, rabbit and rat. Phytomedicine 2008, 15(1–2):44–54
-
Gauthaman K, Ganesan AP, Prasad RN: Sexual effects of puncturevine (Tribulus terrestris) extract (protodioscin): an evaluation using a rat model. J Altern Complement Med 2003, 9(2):257–265.
-
Pytel Y, Vinarov A, Lopatkin N, Sivkov A, Gorilovsky L, Raynaud J: Long-term clinical and biological effects of the liposterolic extract of serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv Ther 2002, 19(6):297–306.
-
Estrada-Reyes R, Ortiz-López P, Gutiérrez-Ortíz J, Martínez-Mota L: Turnera diffusa Wild (Turneraceae) recovers sexual behavior in sexually exhausted males. J Ethnopharmacol 2009, 123(3):423–429
-
Liu WJ, Xin ZC, Xin H, Yuan YM, Tian L, Guo YL: Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. Asian J Androl 2005, 7(4):381–388
-
Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC: Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998, 159(5):1541–1547.
-
Santaella RM, Fraunfelder FW: Ocular adverse effects associated with systemic medications: recognition and management. Drugs 2007, 67(1):75–93.
-
Althof SE, Corty EW, Levine SB, Levine F, Burnett AL, McVary K, Stecher V, Seftel AD: EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999, 53(4):793–799.
-
Montorsi P, Ravagnani PM, Galli S, Rotatori F, Briganti A, Salonia A, Dehò F, Montorsi F: Common grounds for erectile dysfunction and coronary artery disease. Curr Opinion Urol 2004, 14:361–365.
-
Heruti R, Shochat T, Tekes-Manova D, Ashkenazi I, Justo D: Prevalence of erectile dysfunction among young adults: results of a large-scale survey. J Sex Med 2004, 1(3):284–291.
-
Gott M, Hinchliff S: Barriers to seeking treatment for sexual problems in primary care: a qualitative study with older people. Fam Pract 2003, 20(6):690–695.
-
Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A, Galli S, Ravagnani PM, Montorsi P: Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003, 44:360–365.
-
Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A, Salonia A, Deho F, Rigatti P, Montorsi F, Fiorentini C: Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J 2006, 27:2632–2639
-
Moyad MA: Dietary supplements and other alternative medicines for erectile dysfunction. What do I tell my patients? Urol Clin North Am 2002, 29(1):11–22. vii.
- Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, Wang T: for the GSSAB Investigators’ Group: Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005, 17:39–57.
-
Shamloul R: Natural aphrodisiacs. J Sex Med 2010, 7:39–49
-
McKay D: Nutrients and botanicals for erectile dysfunction: examining the evidence. Altern Med Rev 2004, 9(1):4–16
-
Villafranco JE, Bond K: Dietary supplement labeling and advertising claims: are clinical studies on the full product required? Food Drug Law J 2009, 64(1):43–67.
-
Fleshner N, Harvey M, Adomat H, Wood C, Eberding A, Hersey K, Guns E: Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. J Urol 2005, 174(2):636–641.
-
Chitaley K, Webb RC, Mills TM: The ups and downs of Rho-kinase and penile erection: upstream regulators and downstream substrates of rhokinase and their potential role in the erectile response. Int J Impot Res 2003, 15:105–109.
-
Rosen R, Riley A, Wagner G, Osterloh I, Kirkpatrick J, Mishra A: The international index of erectile function (IIEF): a multidimensional scalefor assessment of erectile dysfunction. Urology 1997, 49:822–830.
- Thurairaja R, Barrass B, Persad R: Internet websites selling herbal treatments for erectile dysfunction. Int J Impot Res 2005, 17(2):196–200
- Vickers A, Zollman C, Lee R: Herbal medicine. West J Med 2001, 175(2):125–128
-
Hong B, Ji YH, Hong JH, Nam KY, Ahn TY: A double-blind crossover study evaluating the efficacy of korean red ginseng in patients with erectile
-
Gauthaman K, Adaikan PG, Prasad RN: Aphrodisiac properties of Tribulus Terrestris extract (Protodioscin) in normal and castrated rats. Life Sci 2002, 71(12):1385–1396
-
Adimoelja A, Ganeshan AP: Protodioscin from herbal plant Tribulus terrestris L improves the male sexual functions, probably via DHEA. Int J Impot Res 1997, 9(supp 1):S1–S70.
-
Arletti R, Benelli A, Cavazzuti E, Scarpetta G, Bertolini A: Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexualbehavior of male rats. Psychopharmacology (Berl) 1999, 143(1):15–19.
-
Paick JS, Lee JH: An experimental study of the effect of Ginkgo biloba extract on the human and rabbit corpus cavernosum tissue. J Urol 1996, 156:1876–1880
-
Tian L, Xin ZC, Liu WJ, Yang YM, Liu G, Chen L, Fu J, Wang LL: Effects of icariin on the erectile function and expression of nitrogen oxide synthase isoforms in corpus cavernosum of arterigenic erectile dysfunction rat model. Zhonghua Yi Xue Za Zhi 2004, 84(11):954–957.
-
Fransen HP, Pelgrom SM, Stewart-Knox B, de Kaste D, Verhagen H: Assessment of health claims, content, and safety of herbal supplements containing Ginkgo biloba. Food Nutr Res 2010, 54. doi:10.3402/fnr.v54i0.5221.
-
Heaton J, Hackett GI, Savage D, Padley RJ: Patient choice is critical in managing erectile dysfunction. Eur Urol 2002, 3(Suppl. 1):33–37
-
Giannitsas K, Konstantinopoulos A, Patsialas C, Perimenis P: Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. Patient Preferences and Adherence 2008, 2:149–155
-
Gazzaruso C, Giordanetti S, De Amici E, Bertone G, Falcone C, Geroldi D, Fratino P, Solerte SB, Garzaniti A: Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004, 110(1):22–26.
-
Moore TM, Strauss JL, Herman S, Donatucci CF: Erectile Dysfunction in Early, Middle, and Late Adulthood: Symptom Patterns and Psychosocial Correlates. J Sex Marital Ther 2003, 29(5):381–399.
-
Montorsi P, Montorsi F, Schulman CC: Is erectile dysfunction the ‘tip of the iceberg’ of a systemic vascular disorder? Eur Urol 2003, 44:352–354
-
Sun P, Cameron A, Seftel A, Shabsigh R, Niederberger C, Guay A: Erectile dysfunction–an observable marker of diabetes mellitus? A large national epidemiological study. J Urol 2006, 176(3):1081–1085
-
Lizza EF, Rosen RC: Definition and classification of erectile dysfunction: Report of the nomenclature committee of the International Society of Impotence Research. Int J Impot Res 1999, 11:141–143.
